Fabric Genomics Expands Commercial Leadership With New Clinical Customers Across the Globe

Fabric Genomics™, the global leader in clinical
interpretation of genomic data, announced that its proprietary clinical
genomics platform has been selected by 10 new commercial partners across
four continents, including Africa, Asia, Europe and North America. The
company’s software is allowing these organizations to provide genomics
leadership and state-of-the art clinical genomics testing in their
respective countries.

The new customers consist of hospitals, clinical laboratories and
research centers located in South Africa, Saudi Arabia, Japan, Iceland,
Denmark, England and Canada. After conducting rigorous technical
evaluations and obtaining competitive bids, each organization has
adopted Fabric Genomics’ end-to-end software platform, which provides
rapid and accurate interpretation for hereditary diseases and oncology
and allows clinicians and researchers to scale up genomic workflows from
initial testing to final reports. The Fabric Enterprise™
technology has been developed and optimized through initial partnerships
with Genomics England and the UK 100,000 Genomes Project as well as with
high-throughput clinical laboratories such as LabCorp.

The partnership with the Centre for Proteomic and Genomic Research
(CPGR) in Cape Town, South Africa, marks Fabric Genomics’ first on the
African continent. Fabric Enterprise’s platform is enabling CPGR to
deliver genomic medicine solutions on par with those enjoyed by many
developed countries outside of Africa. Effective analysis of results and
variants generated by NGS technologies is an essential component in
generating clinical reports with good quality and utility.

“Fabric’s expertise in working with leading genomics centers across the
world, and its ability to integrate with DRAGEN, has allowed us to
develop a fast, automated and best-practice data analysis and reporting
pipeline,” said Reinhard Hiller, PhD, managing director of CPGR and its
precision medicine subsidiary, Artisan Biomed. “As a consequence, we
have a fit-for-purpose solution for the South African health care system
and beyond. Fabric employs a systematic yet rapid approach to variant
interpretation, making it ideally suitable for training and capacity
development for health care practitioners on the continent.”

King Fahad Medical City (KFMC), in Riyadh City, Saudi Arabia, is the
country’s largest Ministry of Health hospital system and represents
Fabric Genomics’ first customer in the Middle East. Through its
Molecular Pathology – Genetics arm, KFMC is using the company’s genomics
platform to conduct whole exome testing to identify known and novel
pathogenic aberrations in patients with a wide range of phenotypes.

“This is a very exciting time for us,” said Manar Samman, PhD,
Consultant and Head of KFMC’s Molecular Pathology laboratory. “The
adoption of Fabric Genomics’ Enterprise solution will enable our team to
streamline our workflow and more quickly analyze and classify variant
data and generate clinical reports. We will be able to provide our
patients with more accurate detection, which will allow us to offer more
personalized treatment and risk assessment.”

“We’re thrilled that our platform can play a part in improving the
health of people across the globe,” said Martin Reese, PhD, CEO of
Fabric Genomics. “Our goal is to make precision medicine the standard of
care for all patients, and to provide clinicians and researchers with
the tools they need to make that standard a clinical reality.”

In addition to the institutions above, the new customers include:
Sheffield Diagnostic Genetics Service (SDGS), a service of Sheffield
Children’s NHS Foundation Trust, and Cancer Research UK Manchester
Institute, both in England; Children’s Hospital of Eastern Ontario –
Research Institute and the University of Calgary’s Department of Medical
Genetics, both in Canada; Landspitali, the National University Hospital
of Iceland; the Kennedy Center (Clinical Genetics Clinic) in Glostrup,
Denmark; and the National Center for Global Health and Medicine (NCGM)
and a2 sigma, both in Japan.

Note to media:

The partnership between Fabric Genomics and Sheffield Diagnostic
Genetics Service will be discussed by Matthew Parker, PhD, SDGS’ former
lead bioinformatician, at the European
Human Genetics Conference to be held in Milan, Italy, June 16th
– 19th. Dr. Parker will talk about SDGS’s new clinical test
for congenital metabolic disorders, and Fabric Genomics’ role as
interpretation provider for the test. The satellite symposium, Accurate
and Rapid Genome Interpretation in Clinical Care, will be held on
Sunday, June 17th, from 3 p.m. – 4:30 p.m.

About Fabric Genomics

Fabric Genomics is making genomics-driven precision medicine a reality.
The company provides clinical decision-support software that enables
clinical labs, hospital systems and country-sequencing programs to gain
actionable genomic insights, resulting in faster and more accurate
diagnoses and reduced turnaround time. Fabric’s end-to-end genomic
analysis platform incorporates proven AI algorithms, and has
applications in both hereditary disease and oncology. Headquartered in
Oakland, California, Fabric Genomics was founded by industry veterans
and innovators with a deep understanding of bioinformatics, large-scale
genomics and clinical diagnostics. To learn more, visit www.fabricgenomics.com
and follow us on Twitter, LinkedIn, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005135/en/